Table 2.

Summary of factors evaluated univariately for an association with death due to melanoma among patients with invasive melanoma.

Factor	No. of patients who died due to melanoma	Hazard ratio (95% CI)	P-value
Year of diagnosis †	42	0.66 (0.59, 0.75)‡	<0.001
Age at diagnosis	42	1.09 (0.85, 1.40)‡	0.50
Sex
Female (N=317)	10	Referent
Male (N=342)	32	2.95 (1.45, 6.00)	0.003
Pathologic stage (8th edition)
I (N=586)	17	Referent
II (N=35)	10	12.29 (5.61, 26.91)	<0.001
III or IV (N=31)	13	19.36 (9.37, 40.02)	<0.001
Not documented (N=7)	2	--
Breslow depth
≤1.00 (N=532)	8	Referent
1.01–2.00 (N=68)	12	11.81 (4.83, 28.90)	<0.001
2.01–4.00 (N=31)	12	34.73 (14.14, 85.35)	<0.001
>4.00 (N=14)	5	32.41 (10.59, 99.20)	<0.001
Not documented (N=14)	5	--

^†Among the patients with invasive melanoma not known to be deceased at the time of this analysis the median (IQR, interquartile range) duration of follow-up by decade of diagnosis was 44.7 (IQR, 42.8–46.7) years for 1970–79, 36.8 (IQR, 35.1–39.1) years for 1980–89, 25.1 (IQR, 22.8–26.9) years for 1990–99, 14.0 (IQR, 12.6–16.8) years for 2000–09, and 5.5 (IQR, 3.2–8.5) years for 2010–2020. A more recent diagnosis was significantly associated with a decreased risk of death due to melanoma (HR 0.64 per 5-year increase in calendar year of diagnosis, 95% CI 0.56–0.74) in a sensitivity analysis focusing on just the first 5 years of follow-up per patient.

^‡Hazard ratio per 5-year increase in calendar year and per 5-year increase in age, respectively.